Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST

Chart of the Week: Hepatitis C – Gilead Wins

by

In honor of Gilead‘s newly approved, and cheaper, hepatitis C drug we decided to show the biomarker, trial and company landscape for hepatitis C. You can read more about Gilead’s new drug herehere and here.

For a larger version of the chart (SVG) click here.

Purple: Company

Red: Trials

Blue: Biomarkers

Green: Disease

hepC_image.png

Share this Image On Your Site

<p><strong>Please include attribution to amplion.com with this graphic.</strong><br /><br /><a href=’http://www.amplion.com/biomarker-trends/chart-of-the-week-hepatitis-c-gilead-wins’><img src=’https://www.amplion.com/wp-content/uploads/2016/06/hepC_image.png’ alt=’Hepatitis C – Gilead Wins’ width=’540px’ border=’0′ /></a></p>

For a refresher on Amplion and BiomarkerBase:

REQUEST A MEETING